Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yindan Xintai Dropping Pill case registry study for angina pectoris
ChiCTR1900022480Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial Hospital of Traditional Chinese Medicine
- Start
- May 2019
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Yindan Xintai Dropping Pill in angina pectoris and coronary arteriosclerosis, sponsored by Jiangsu Provincial Hospital of Traditional Chinese Medicine. Primary endpoints: Curative effect of angina pectoris and Stopping and decreasing of nitroglycerin. Planned start May 2019; status: not yet recruiting.
02
Drugs
Yindan Xintai Dropping Pill
03
Conditions
angina pectoriscoronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR1900022480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022480.